European Medicines Agency fast-tracks review of INBRAIN graphene DBS for Parkinson's

Summary

The EMA has granted PRIME designation to INBRAIN Neuroelectronics' graphene-based DBS system for Parkinson's disease, enabling accelerated regulatory dialogue and potential priority review. PRIME designation, equivalent to FDA Breakthrough Device, is the first awarded to a graphene neural interface and only the third for any DBS technology.